Close
Found 0 results for your search. Showing 0 to 0.
No results could be found for your search.
x Close Search
Close

Publications

Plasma proteomics for biomarker discovery in childhood tuberculosis.
Fossati, A; Wambi, P; Jaganath, D; Calderon, R; Castro, R; Mohapatra, A; McKetney, J; Luiz, J; Nerurkar, R; NKEREUWEM, E; Franke, MF; Mousavian, Z; Collins, JM; Sigal, GB; Segal, MR; Kampman, B; Wobudeya, E; Cattamanchi, A; Ernst, JD; Zar, HJ; Swaney, DL; COMBO Study Consortium,;
2025
Nature communications, (2025).16, 10.1038/s41467-025-61515-5.
Within-country heterogeneity in patterns of social contact relevant for tuberculosis infection transmission, prevention, and care.
LEGRAND, KE; Edwards, A; Mohlamonyane, M; Dayi, N; Olivier, S; Gareta, D; Wood, R; GRANT, AD; WHITE, RG; Middelkoop, K; KHAN, P; MCCREESH, N;
2025
PLOS global public health, (2025).5 7 10.1371/journal.pgph.0004257.
Risk of rifampicin resistance emergence after incomplete first-line tuberculosis treatment.
Dupuis, GN; Dolynska, M; Chiang, SS; Horsburgh, CR; STAGG, HR; Rybak, NR; Petrenko, V; Jenkins, HE;
2025
European respiratory journal, (2025).66 1 10.1183/13993003.00902-2025.
Blood RNA biomarkers and C-reactive protein for triage of adult patients with tuberculosis lymphadenitis and pericarditis in South Africa: a single-centre, prospective, observational, diagnostic accuracy study.
Mann, T; Minnies, S; Gupta, RK; Reeve, BW P; Nyawo, G; Palmer, Z; Naidoo, C; Doubell, A; Pecoraro, A; John, T-J; Schubert, P; CALDERWOOD, CJ; Chandran, A; Theron, G; Noursadeghi, M;
2025
The Lancet. Microbe, (2025).6 9 10.1016/j.lanmic.2025.101153.
The potential impact of reductions in international donor funding on tuberculosis in low-income and middle-income countries: a modelling study.
CLARK, RA; MCQUAID, CF; Richards, AS; Bakker, R; SUMNER, T; Prŷs-Jones, TO; HOUBEN, RM G J; WHITE, RG; HORTON, KC;
2025
The Lancet Global health, (2025).13 9 10.1016/S2214-109X(25)00232-3.
PPE50 variants as novel phylogeographic signatures of host-pathogen co-evolution in tuberculosis.
D'Souza, C; PHELAN, JE; Gomez-Gonzalez, P-J; THORPE, J; CLARK, TG; Tsolaki, AG;
2025
Communications biology, (2025).8 1 10.1038/s42003-025-08383-3.
Authors' reply "Lessons from tuberculosis history".
De Vries, G; HOUBEN, RM G J; Esmail, H;
2025
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, (2025).158, 10.1016/j.ijid.2025.107977.
Temporal trends of SARS-CoV-2 exposure in adolescents: a longitudinal pilot study nested in a Uganda birth cohort.
ZIRIMENYA, L; Nassuuna, J; Namutebi, M; Zziwa, C; Serubanja, J; Nsubuga, D; Kiwudhu, F; Akello, F; Tumusiime, J; Ninsiima, C; Oduru, G; Kabami, G; Akurut, H; Nakyesige, R; Kimuda, S; WAJJA, A; NKURUNUNGI, G; SERWANGA, J; Doores, KJ; WEBB, EL; ELLIOTT, AM;
2025
NIHR open research, (2025).5, 10.3310/nihropenres.13986.1.
Implications of progressive lung damage and post-tuberculosis sequelae for the health benefits of prompt tuberculosis treatment in high HIV prevalence settings: a mathematical modelling analysis.
Can, MH; SWEENEY, S; Allwood, BW; Dorman, SE; Cohen, T; Menzies, NA;
2025
The Lancet Global Health, (2025).13 7 10.1016/S2214-109X(25)00114-7.
Evidence required to evaluate the use of bacteriologically confirmed asymptomatic tuberculosis disease as a primary endpoint in prevention of tuberculosis disease vaccine licensure trials.
WHITE, RG; Churchyard, GJ; HORTON, KC; Fiore-Gartland, A; Behr, MA; CLARK, RA; Cobelens, F; Ernst, JD; Esmail, H; Garcia-Basteiro, AL; Hadinegoro, SR; Hanekom, WA; Hatherill, M; Hill, PC; Muloiwa, R; Pelzer, PT; Rangaka, L; Rees, H; Schrager, L; Stanley, M; Tufet, M; Wong, EB; HOUBEN, RM G J;
2025
The Lancet. Respiratory medicine, (2025).13 10 10.1016/S2213-2600(25)00164-X.